全文获取类型
收费全文 | 5912篇 |
免费 | 520篇 |
国内免费 | 4篇 |
出版年
2023年 | 42篇 |
2022年 | 78篇 |
2021年 | 185篇 |
2020年 | 118篇 |
2019年 | 124篇 |
2018年 | 142篇 |
2017年 | 135篇 |
2016年 | 183篇 |
2015年 | 351篇 |
2014年 | 382篇 |
2013年 | 369篇 |
2012年 | 544篇 |
2011年 | 535篇 |
2010年 | 291篇 |
2009年 | 269篇 |
2008年 | 333篇 |
2007年 | 284篇 |
2006年 | 264篇 |
2005年 | 223篇 |
2004年 | 212篇 |
2003年 | 176篇 |
2002年 | 148篇 |
2001年 | 50篇 |
2000年 | 39篇 |
1999年 | 44篇 |
1998年 | 38篇 |
1997年 | 30篇 |
1996年 | 35篇 |
1995年 | 25篇 |
1994年 | 32篇 |
1993年 | 29篇 |
1992年 | 47篇 |
1991年 | 26篇 |
1990年 | 32篇 |
1989年 | 41篇 |
1988年 | 31篇 |
1987年 | 27篇 |
1986年 | 25篇 |
1985年 | 25篇 |
1984年 | 19篇 |
1983年 | 20篇 |
1982年 | 23篇 |
1981年 | 28篇 |
1980年 | 24篇 |
1979年 | 32篇 |
1978年 | 19篇 |
1977年 | 21篇 |
1976年 | 20篇 |
1975年 | 22篇 |
1974年 | 16篇 |
排序方式: 共有6436条查询结果,搜索用时 15 毫秒
1.
2.
On the structure and chromosome location of the 72- and 92-kDa human type IV collagenase genes. 总被引:4,自引:0,他引:4
The 72- and 92-kDa type IV collagenases are members of a group of secreted zinc metalloproteases. Two members of this family, collagenase and stromelysin, have previously been localized to the long arm of chromosome 11. Here we assign both of the two type IV collagenase genes to human chromosome 16. By sequencing, the 72-kDa gene is shown to consist of 13 exons, 3 more than have been reported for the other members of this gene family. The extra exons encode the amino acids of the fibronectin-like domain which has so far been found in only the 72- and 92-kDa type IV collagenase. The evolutionary relationship among the members of this gene family is discussed. 相似文献
3.
Roger Collier 《CMAJ》2009,181(5):E73-E74
4.
Roger Collier 《CMAJ》2010,182(9):E387-E388
5.
Roger Collier 《CMAJ》2009,181(12):E283-E284
6.
7.
8.
Emily Olfson Catherine E. Cottrell Nicholas O. Davidson Christina A. Gurnett Jonathan W. Heusel Nathan O. Stitziel Li-Shiun Chen Sarah Hartz Rakesh Nagarajan Nancy L. Saccone Laura J. Bierut 《PloS one》2015,10(9)
The American College of Medical Genetics and Genomics (ACMG) recommends that clinical sequencing laboratories return secondary findings in 56 genes associated with medically actionable conditions. Our goal was to apply a systematic, stringent approach consistent with clinical standards to estimate the prevalence of pathogenic variants associated with such conditions using a diverse sequencing reference sample. Candidate variants in the 56 ACMG genes were selected from Phase 1 of the 1000 Genomes dataset, which contains sequencing information on 1,092 unrelated individuals from across the world. These variants were filtered using the Human Gene Mutation Database (HGMD) Professional version and defined parameters, appraised through literature review, and examined by a clinical laboratory specialist and expert physician. Over 70,000 genetic variants were extracted from the 56 genes, and filtering identified 237 variants annotated as disease causing by HGMD Professional. Literature review and expert evaluation determined that 7 of these variants were pathogenic or likely pathogenic. Furthermore, 5 additional truncating variants not listed as disease causing in HGMD Professional were identified as likely pathogenic. These 12 secondary findings are associated with diseases that could inform medical follow-up, including cancer predisposition syndromes, cardiac conditions, and familial hypercholesterolemia. The majority of the identified medically actionable findings were in individuals from the European (5/379) and Americas (4/181) ancestry groups, with fewer findings in Asian (2/286) and African (1/246) ancestry groups. Our results suggest that medically relevant secondary findings can be identified in approximately 1% (12/1092) of individuals in a diverse reference sample. As clinical sequencing laboratories continue to implement the ACMG recommendations, our results highlight that at least a small number of potentially important secondary findings can be selected for return. Our results also confirm that understudied populations will not reap proportionate benefits of genomic medicine, highlighting the need for continued research efforts on genetic diseases in these populations. 相似文献
9.
J Collier 《Philosophical transactions of the Royal Society of London. Series B, Biological sciences》2001,356(1416):1945-1946
This paper offers an alternative view to that given elsewhere regarding the value of zanamivir as an agent for treating patients who develop influenza symptoms. The position taken here has developed as a result of an analysis of the data that was undertaken by the journal Drug and Therapeutics Bulletin. 相似文献
10.